Trial reportThe international journal of neuropsychopharmacology2009
Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation.
Trial report in The international journal of neuropsychopharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Opioid antagonists for smoking cessation.The Cochrane database of systematic reviews · 2013Pooled it
- Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?Addiction (Abingdon, England) · 2013Pooled it
- Efficacy of Combining Varenicline and Naltrexone for Smoking Cessation and Drinking Reduction: A Randomized Clinical Trial.The American journal of psychiatry · 2021Trial
- Cannabis use during alcohol treatment is associated with alcohol-related problems one-year post-treatment.Drug and alcohol dependence · 2018Trial
- Nicotine-Use/Smoking Is Associated with the Efficacy of Naltrexone in the Treatment of Alcohol Dependence.Alcoholism, clinical and experimental research · 2018Trial
- Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017Trial
- A Double-Blind Randomized Placebo-Controlled Trial of Oral Naltrexone for Heavy-Drinking Smokers Seeking Smoking Cessation Treatment.Alcoholism, clinical and experimental research · 2017Trial
- Combined varenicline and naltrexone treatment reduces smoking topography intensity in heavy-drinking smokers.Pharmacology, biochemistry, and behavior · 2015Trial
- Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings.The American journal of drug and alcohol abuse · 2015Trial
- Naltrexone improves quit rates, attenuates smoking urge, and reduces alcohol use in heavy drinking smokers attempting to quit smoking.Alcoholism, clinical and experimental research · 2014Trial
- Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings.Psychopharmacology · 2014Trial
- Effects of the opioid receptor antagonist naltrexone on smoking and related behaviors in smokers preparing to quit: a randomized controlled trial.Addiction (Abingdon, England) · 2013Trial
- Naltrexone reduction of long-term smoking cessation weight gain in women but not men: a randomized controlled trial.Biological psychiatry · 2013Trial
- Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence.Biological psychiatry · 2012Trial
- Marijuana use and tobacco smoking cessation among heavy alcohol drinkers.Drug and alcohol dependence · 2011Trial
- Low-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: a randomized trial.Drug and alcohol dependence · 2010Trial
- Naltrexone decreases heavy drinking rates in smoking cessation treatment: an exploratory study.Alcoholism, clinical and experimental research · 2009Trial
- Effects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users: A Preliminary Laboratory Study.Journal of addiction medicineTrial
- App-based contingency management to reduce heavy drinking days among smokers receiving varenicline: Feasibility, acceptability, and efficacy indicators from a phase I analog trial.Experimental and clinical psychopharmacology · 2026Article
- Beyond mediators: A critical review and methodological path forward for studying mechanisms in alcohol use treatment research.Alcohol, clinical & experimental research · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
The opiate antagonist naltrexone (Ntx) has demonstrated efficacy in the treatment of alcohol dependence and as a component of treatment to reduce heavy drinking. At present, there are no published dose-ranging clinical trials of the oral preparation for treatment of problem drinking. The present study evaluated the effects of Ntx on alcohol use among the subset of hazardous drinkers (n=102) who participated in a placebo-controlled, dose-ranging trial of oral Ntx (25-mg, 50-mg and 100-mg doses) combined with open-label transdermal nicotine patch for enhancing smoking cessation. On the primary outcome--no hazardous drinking (drinking that exceeded weekly or daily limits) during treatment--25 mg and 50 mg Ntx were superior to placebo (each p<0.05). These findings remained after controlling for baseline predictors or smoking abstinence during treatment. Time to remission of hazardous drinking was examined as a secondary outcome with definitions of hazardous drinking based on weekly limits, daily limits and the combination of weekly and daily limits and the results were consistent with the primary findings. In conclusion, the findings suggest that Ntx can reduce the risk of hazardous drinking in smokers who are not seeking or receiving alcohol treatment, providing strong evidence for the pharmacological effects of Ntx on drinking. This effect appears to favour lower doses that may be better tolerated and less expensive than the higher 100-mg dose. Given its efficacy and favourable side-effect profile, the 25-mg dose should be considered for future studies of combination therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.